Treatment Support Kits Are Designed with Patient Therapies in Mind

In this clip, Jamie Fritz, RPh, Retail Pharmacy Manager at Compass Oncology, explains the treatment support kit committee of the National Community Oncology Dispensing Association (NCODA), and how these kits are designed for each specific patient.


So, our treatment support kits are kits that are designed with the patient in mind. So, anytime a patient starts with a new therapy they receive a treatment support kit that is designed specifically for the medication they’re on and the potential side effects they could have. So, with NCODA we develop the treatment support kits with number one the patient in and the medication they’re on. So, if the side effect were diarrhea, we would include some loperamide, or skin cream for hand foot syndrome with capecitabine. So, through NCODA and the treatment support kit committee, we’re developing kits that make sense for the patient and the therapy that they’re going to be on. 



Related Articles

The supplemental New Drug Application supports the expansion of niraparib’s indication as a late-line therapeutic option for patients with ovarian cancer.
Compared with nontargeted therapy, targeted therapies demonstrated a survival advantage for patients 65 years and older with metastatic renal cell carcinoma.
Patients with multiple sclerosis who switched disease-modifying treatments at least twice had a higher relative risk of developing cancer.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.